Tom Reeve Academic Surgical Clinic  ·  St Leonards

Site language
02 9438 2277
Thomas J. HughSpecialist Hepato-Biliary & General Surgeon
Site language

Conditions · Gallbladder cancer

Gallbladder cancer

Gallbladder cancer is uncommon but is the most prevalent malignancy of the biliary tract worldwide. Professor Tom Hugh provides specialist hepatobiliary assessment in St Leonards, with surgery at Royal North Shore Hospital and North Shore Private Hospital when appropriate.

<3 /100k

Typical incidence in many populations

Gallstones

A major recognised risk factor

Resection

Only curative treatment when feasible

MDT

Complex cases discussed in cancer teams

Page last reviewed July 2026. Figures below summarise published epidemiology and symptom ranges used in specialist practice summaries.

/ 01Overview

What is gallbladder cancer?

Gallbladder cancer (GBC) is a relatively rare disease with incidence often under 3 per 100,000, though rates vary by geography, ethnicity and sex. High incidence is reported in some indigenous populations of the Americas, Central Europe and Northern India, populations that also have high rates of cholesterol gallstone disease.

Main risk factors include:

  • Long-standing gallstones
  • Chronic biliary tract infections
  • Female sex
  • Large gallbladder polyps
  • Anomalous pancreato-biliary duct junction
/ 02Symptoms

Why is early diagnosis difficult?

Symptoms are often non-specific. Presentation can resemble biliary colic or cholecystitis, so GBC is sometimes diagnosed incidentally after routine cholecystectomy for presumed benign disease. Aggressive local spread means many cases are found at an advanced stage.
  • Persistent right upper quadrant or epigastric pain (reported in about 54–83% of cases)
  • Jaundice (about 10–46%)
  • Nausea and vomiting (about 15–43%)
  • Anorexia (about 4–41%)
  • Weight loss (about 10–39%)

Overall five-year survival for advanced disease is reported as less than 5% in published summaries. Radical resection remains the only curative treatment when it is feasible.

/ 03Bile duct cancer

What about cancer in the bile duct (cholangiocarcinoma)?

Cancer can develop in any part of the bile duct. Location guides treatment: extrahepatic disease may need duct excision with local lymph nodes; hilar (Klatskin) tumours and peripheral intrahepatic tumours often require liver resection when operable.

Postoperative chemotherapy is commonly used. When the cancer cannot be removed, bile drainage may be restored with a stent through the narrowed duct, and palliative chemotherapy may be offered. Care is coordinated through multidisciplinary teams listed on Professor Hugh’s about page.

/ 04Common questions

It is relatively uncommon overall, with estimated incidence under 3 per 100,000 in many populations, but rates vary by geography, ethnicity and sex. It is the most prevalent malignancy of the biliary tract worldwide.

Early symptoms are non-specific and can resemble biliary colic or cholecystitis. Some cancers are found incidentally after cholecystectomy for presumed benign disease. Advanced disease at diagnosis is associated with a poorer prognosis.

Radical resection of the gallbladder (and appropriate adjacent tissue when indicated) is the only curative treatment. Other options are limited when the tumour cannot be removed.

Cholangiocarcinoma can arise outside the liver, at the liver hilum (Klatskin tumour), or within the liver. Treatment may involve duct excision with lymph nodes, liver resection, stenting for drainage, and chemotherapy depending on location and stage.

/ 05Related reading

External authority: Gallbladder cancer information, Cancer Institute NSW.